Danalioglu Ahmet, Kaymakoglu Sabahattin, Mungan Zeynel, Karaca Cetin, Demir Kadir, Durakoglu Ziyaettin, Besisik Fatih, Boztas Gungor, Cakaloglu Yilmaz, Okyen Atilla
Istanbul University, Istanbul School of Medicine, Gastroenterohepatology Department, Turkey.
Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccxcviii-ccc.
BACKGROUND/AIMS: Cyclosporin-A is used as alternative medical therapy in steroid refractory ulcerative colitis with severe activity. In spite of known effectivity, the long term results of cyclosporin-A therapy is not clear for today.
The results of 13 steroid refractory patients that treated with cyclosporin-A were retrospectively assessed. Cyclosporin-A was started as orally, 8 mg/kg/day in 4 patients and intravenously, 4 mg/kg/day in 9 patients. Intravenous therapy changed to oral therapy one week after beginning. Patients also received 5-ASA and azathioprine. Steroid was tapered.
Ten patients responded to treatment in a mean of 9 days (range: 2-30 days). Three unresponded patients underwent total colectomy on 7, 11 and 19th day of therapy. Ten initially responded patients received the drug for average 4.9 months. Of these, four relapsed during and one relapsed soon after therapy. Four of 5 relapser patients underwent colectomy. One patient that not accepted surgical intervention is still receiving medical therapy. Remaining 5 patients, 38% of total group; 50% of patients that initially responded, maintain the remission at the end of average 17 months of follow up period.
Cyclosporin-A therapy in severe ulcerative colitis that is refractory to steroids, provides initial remission in 80% of patients and allows 40% to retain their colon for 1 year.
背景/目的:环孢素A被用作重度活动性类固醇难治性溃疡性结肠炎的替代药物治疗。尽管已知其有效性,但目前环孢素A治疗的长期结果尚不清楚。
对13例接受环孢素A治疗的类固醇难治性患者的结果进行回顾性评估。4例患者开始口服环孢素A,剂量为8mg/kg/天,9例患者开始静脉注射,剂量为4mg/kg/天。静脉治疗开始一周后改为口服治疗。患者还接受了5-氨基水杨酸和硫唑嘌呤治疗。逐渐减少类固醇用量。
10例患者平均在9天(范围:2 - 30天)内对治疗有反应。3例无反应的患者在治疗的第7、11和19天接受了全结肠切除术。10例最初有反应的患者平均接受药物治疗4.9个月。其中,4例在治疗期间复发,1例在治疗后不久复发。5例复发患者中有4例接受了结肠切除术。1例未接受手术干预的患者仍在接受药物治疗。其余5例患者,占总组的38%;占最初有反应患者的50%,在平均17个月的随访期结束时维持缓解状态。
环孢素A治疗对类固醇难治的重度溃疡性结肠炎,可使80%的患者获得初始缓解,并使40%的患者保留结肠达1年。